🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,063 results for “BRIGHT MINDS BIOSCIENCES INC.” Clear

  1. 42 mg transdermal nicotine replacement

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  2. 5 A

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Cessation

    phase 2 other completed

    1 trial

  3. AEF0117

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  4. ATM

    BRIGHT MINDS BIOSCIENCES INC.

    Dual Diagnosis

    phase 2 other completed

    1 trial

  5. Active Cannabis

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis

    phase 2 small molecule on hold

    1 trial

  6. Active rTMS

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 2 other completed

    1 trial

  7. Adderall-XR and Topiramate

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  8. Alprazolam

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Interactions

    phase 2 small molecule active

    1 trial

  9. Aprepitant

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 2 small molecule completed

    2 trials

  10. Aripiprazole

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 small molecule completed

    1 trial

  11. Aripiprazole + Cocaine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Abuse

    phase 2 small molecule completed

    1 trial

  12. Assets Getting To Outcomes

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  13. Atomoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 2 small molecule completed

    1 trial

  14. Atomoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  15. Atomoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  16. B013

    BRIGHT MINDS BIOSCIENCES INC.

    Platinum-resistant Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  17. BMB-101

    BRIGHT MINDS BIOSCIENCES INC.

    Absence Epilepsy

    phase 2 small molecule active

    1 trial

  18. BMB-101

    BRIGHT MINDS BIOSCIENCES INC.

    Prader-Willi Syndrome

    phase 2 small molecule active

    1 trial

  19. BVRS-GamVac-Combi

    BRIGHT MINDS BIOSCIENCES INC.

    MERS (Middle East Respiratory Syndrome)

    phase 2 small molecule active

    1 trial

  20. BXCL501 (180 micrograms)

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 2 small molecule active

    1 trial

  21. BZD discontinuation protocol

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 small molecule completed

    1 trial

  22. Baclofen

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Dependence

    phase 2 small molecule completed

    1 trial

  23. Baclofen

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  24. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings

    phase 2 other terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources